scholarly journals Hypoxia-Activated Albumin-Binding Exatecan Prodrug for Cancer Therapy

ACS Omega ◽  
2021 ◽  
Author(s):  
Zhiyang Cheng ◽  
Ying Huang ◽  
Pingxuan Shao ◽  
Lei Wang ◽  
Shulei Zhu ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Albumin Binding

scholarly journals Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health

Diseases ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 28
Author(s):  
Nicolae Ghinea
Keyword(s):  
Cancer Therapy ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Small Molecule ◽  
Receptor Tyrosine Kinase ◽  
Binding Proteins ◽  
Kinase Inhibitors ◽  
Drug Carrier ◽  
Albumin Binding ◽  
Receptor Tyrosine Kinase Inhibitors

Anti-angiogenics currently used in cancer therapy target angiogenesis by two major mechanisms: (i) neutralizing angiogenic factors or their receptors by using macromolecule anti-angiogenic drugs (e.g., therapeutic antibodies), and (ii) blocking intracellularly the activity of receptor tyrosine kinases with small molecule (Mr < 1 kDa) inhibitors. Anti-angiogenics halt the growth and spread of cancer, and significantly prolong the disease-free survival of the patients. However, resistance to treatment, insufficient efficacy, and toxicity limit the success of this antivascular therapy. Published evidence suggests that four albumin-binding proteins (ABPs) (gp18, gp30, gp60/albondin, and secreted protein acidic and cysteine-rich (SPARC)) could be responsible for the accumulation of small molecule receptor tyrosine kinase inhibitors (RTKIs) in normal organs and tissues and therefore responsible for the side effects and toxicity associated with this type of cancer therapy. Drawing attention to these studies, this review discusses the possible negative role of albumin as a drug carrier and the rationale for a new strategy for cancer therapy based on follicle-stimulating hormone receptor (FSHR) expressed on the luminal endothelial cell surface of peritumoral blood vessels associated with the major human cancers. This review should be relevant to the audience and the field of cancer therapeutics and angiogenesis/microvascular modulation-based interventions.

scholarly journals A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy

Theranostics ◽  
2018 ◽  
Vol 8 (7) ◽  
pp. 2018-2030 ◽  
Author(s):  
Lingling Shan ◽  
Xin Zhuo ◽  
Fuwu Zhang ◽  
Yunlu Dai ◽  
Guizhi Zhu ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Albumin Binding ◽  
Targeted Cancer Therapy

Multifunctional metal–organic framework heterostructures for enhanced cancer therapy

2021 ◽  
Author(s):  
Jintong Liu ◽  
Jing Huang ◽  
Lei Zhang ◽  
Jianping Lei
Keyword(s):  
Cancer Therapy ◽  
General Principle ◽  
Biomedical Applications ◽  
Metal Organic Framework ◽  
Metal Organic ◽  
Functional Modulation ◽  
Organic Framework

We review the general principle of the design and functional modulation of nanoscaled MOF heterostructures, and biomedical applications in enhanced therapy.

Tetracycline Resolves Cancer Therapy Rash

2007 ◽  
Vol 37 (14) ◽  
pp. 23
Author(s):  
KERRI WACHTER
Keyword(s):  
Cancer Therapy
Sign in / Sign up

Export Citation Format

Share Document